Seeking Alpha

NPS Pharmaceuticals (NPSP -3.7%) gives back all its premarket gains and more, despite the...

NPS Pharmaceuticals (NPSP -3.7%) gives back all its premarket gains and more, despite the postive Phase 3 results for its hypoparathyroid treatment earlier today. The company has been on a steady downtrend for most of this year, losing nearly 50% since hitting a 52-week high in May.
Comments (1)
  • Christopher Nassar
    , contributor
    Comments (6) | Send Message
     
    NPSP seems like a very good buy at this point. It doesn't seem to have anywhere to go but up. The market can of course be tricky but I see a 90% chance of making a profit here.
    8 Nov 2011, 07:47 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector